Consensus on diagnosis and empiric antibiotic therapy of febrile neutropenia by Giurici, Nagua & Zanazzo, Giulio A.
[Pediatric Reports 2011; 3:e4] [page 11]
Consensus on diagnosis and
empiric antibiotic therapy 
of febrile neutropenia 
Nagua Giurici,1 Giulio A. Zanazzo2
1Department of Pediatrics, IRCCS Burlo
Garofolo, Trieste; 2Department 
of Oncohematology, IRCCS Burlo
Garofolo, Trieste, Italy
Abstract 
Controversial issues on the management of
empiric therapy and diagnosis of febrile neu-
tropenia  (FN)  were  faced  by  a  Consensus
Group of the Italian Association of Pediatric
Hematology-Oncology (AIEOP). In this paper
we  report  the  suggestions  of  the  consensus
process regarding the role of aminoglycosides,
glycopeptides and oral antibiotics in empiric
therapy of FN, the rules for changing or discon-
tinuing  the therapy as well as the timing of
the blood cultures.
Introduction
A survey of 34 AIEOP centers was carried out
in 2010 requesting local policies, protocols and
guidelines  relating  to  the  management  of
febrile neutropenia (FN) in children treated
for malignant disease. The results of the sur-
vey showed variability across centers in many
topics. In order to offer a homogeneous care to
children  treated  for  cancer,  a  consensus
process  was  promoted  by  AIEOP  Supportive
Care and Infectious Disease Groups to settle
the more frequent questions. This paper will
focus on the results regarding empiric antibi-
otic therapy and bacterial diagnosis.
Methods
Consensus process developed step by step.
First step was definition by members of the
AIEOP Supportive Care and Infectious Disease
Groups of most controversial issues. Second
step was a review of literature done by single
members of the Consensus Group. Third step
was the discussion of results by the delegates
of all AIEOP centers in plenary session. At the
end of the plenary meeting AIEOP Consensus
Group made a consensus on the controversial
issues.
Results
Role of aminoglycosides in empiric
therapy
Even in children with high-risk FN, amino-
glycoside-based combined therapies have not
demostrated  superiority  over  monotherapy
with imipemenics1 or with fourth generation
cephalosporines2,3 in  prospectic  randomized
trials.  Nevertheless  many  authorities  have
stressed the potential benefits of antimicrobial
synergism of aminoglycosides in treatment of
gram-negative  bacilli  infections4 or  in  treat-
ment of very high risk patients who present
with  haemodynamic  instability  or  who  have
evidence of multiresistant infection.5
The AIEOP Group agrees with the indica-
tions of a recent pediatric review6 which rec-
ommends aminoglycoside-based therapy in the
following conditions: demonstrated P. aerugi-
nosa infection,  suspected  catheter-related
infection, evidence of sepsis.
Role of glycopeptides in empiric
therapy
Meta analysis of randomized controlled tri-
als on adult population showed that the addi-
tion of anti Gram positive treatment, namely
glycopeptides,  prior  to  documentation  of  a
Gram-positive infection, does not improve out-
comes,7 that glycopeptides should not be rou-
tinely used as part of the initial empiric treat-
ment8 and can be safely deferred until the doc-
umentation of a resistant Gram- positive infec-
tion.9 There are no randomized controlled tri-
als on pediatric population.
The AIEOP Group agrees with the indication
of  an  up-to-date  review6 that  recommends
empiric use of glycopeptides in children with
FN in the following conditions: clinical suspi-
cion of a catheter related infection, skin and
soft tissue infections in areas in which rates of
community acquired MRSA surpass 15%, bone
and  joint  infections,  bacteremia  caused  by
Gram+ cocci before identification and antimi-
crobial susceptibility determination.
Role of oral antimicrobial therapy
Controlled trials showed that there was no
difference in outcome in oral versus iv outpa-
tient therapy in pediatric low risk FN, suggest-
ing  that  amoxicillin-clavulanate  plus
ofloxacin10 or amoxicillin-clavulanate in com-
bination  with  ciprofloxacine11 or  ciproflo  -
xacine  alone12 may  be  the  oral  regimens  of
choice.
The AIEOP Consensus Group remarks the
need  for  an  accurate  definition  of  low  risk
patients prior to accepting the suggestion of
literature. A subgroup of AIEOP was charged
to asses  the various scores suggested by liter-
ature. 
Changes in empiric therapy
Literature on adult population suggests an
assessment after 48 hours of empiric therapy. In
low  risk  apyretic  and  no  longer  neutropenic
patients a switch to oral antibiotics could be
considered, while in high risk apyretic and no
longer  neutropenic  patients  aminoglycosides
could  be  discontinued.  Patients  who  are  still
pyrexial have to continue with initial therapy if
clinically  stable,  while  if  clinically  unstable
require a modification of the antibiotic regimen
(shift  to  carbapemen,  addition  of  gycopep-
tide).13 Given the lack of specific guidelines for
the pediatric population the AIEOP Consensus
Group agrees with these suggestions.
When to discontinue empiric therapy
Literature suggests that antibacterials can
be  discontinued  when  neutrophil  count  is
>500/mmc, the patient is asymptomatic, has
been afebrile for 48 h and blood cultures are
negative.  If  neutrophil  count  remains
<500/mmc and  the patient is asymptomatic
antibacterials can be discontinued after 7 days
of apyrexia.13 AIEOP Consensus Group agrees
with these suggestions.
Utility of peripheral blood cultures 
The utility of peripheral blood cultures in
febrile  neutropenic  children  with  central
venous catheters is controversial. In the large
majority of AIEOP Centres this practice is actu-
ally neglected.
Even though a recent paper14 supports con-
tinuation  of  routine  peripheral  cultures,  the
apparent advantage could be explained with a
larger blood volume collection. In fact low level
bacteremia is common in pediatric population,
requiring the culturing of up to 4 or 4.5% of a
patient's  total  blood  volume  for  the  reliable
detection of pathogens.15,16 AIEOP Consensus
Group concludes that peripheral blood cultures
are  not  necessary  and  exhorts  to  collect  an
adequate blood volume.
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Timing of blood cultures
Recent literature points out that the likeli-
hood of documenting bloodstream infections
was not enhanced by collecting blood at the
time of temperature spikes,17 that surveillance
blood cultures could detect causative microor-
ganisms  in  more  than  one-third  of  blood
stream infections prior to the onset of clinical
manifestations18 and that blood cultures with
an  adequate  blood  volume  were  more  likely
than those with an inadequate blood volume to
yield positive blood culture results.16
In  case  of  FN,  AIEOP  Consensus  Group
advises to collect at least two sets of blood cul-
tures (for aerobe and  anaerobe germs) at a
close interval (15’) independently from tem-
perature spikes immediately prior to the start
of the empiric therapy. 
The AIEOP Consensus Group also exhorts to
collect a total blood volume adequate to the
weigh of patients (6 mL from 2 up to 12 kg; 20
ml from 12 up to 36 kg; 40 mL up to 36 kg).
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